VivoSim Validates ADC Toxicity Models, Aims to Streamline Drug Development
Event summary
- VivoSim presented data at the Society of Toxicology meeting on March 24, 2026, validating its NAMkind™ liver and intestine models for predicting ADC toxicity.
- The models demonstrated close correlation with clinical outcomes for approved ADCs like gemtuzumab ozogomicin and enfortumab vedotin.
- VivoSim's models can detect differential toxicity, linker cleavage, and target engagement in ADCs.
- NAMkind™ services are now available in the US, Europe, Korea, and China, with plans to scale capacity globally.
The big picture
VivoSim's validation of its ADC toxicity models comes as the biotech industry faces increasing pressure to reduce off-target effects in oncology drugs. The FDA's 2025 announcement favoring non-animal testing methods positions VivoSim to capitalize on a regulatory tailwind. The company's ability to detect differential toxicity in ADCs could significantly streamline drug development, reducing late-stage failures and accelerating safer therapies to market.
What we're watching
- Adoption Pace
- How quickly biotech firms will integrate VivoSim's models into ADC development pipelines.
- Regulatory Impact
- Whether the FDA's shift toward NAM methods will accelerate VivoSim's market penetration.
- Competitive Positioning
- The extent to which VivoSim can differentiate itself in the growing ADC toxicity testing market.
Related topics